Human papillomavirus infection is one of the most common viral infections that affect millions of people worldwide, with treatment options ranging from managing visible symptoms like warts to preventing serious complications through regular screening and vaccination.

Managing HPV: What Approaches Are Available Today?

When someone receives a diagnosis of human papillomavirus (HPV) infection, understanding the available treatment approaches becomes essential. The primary goal of treatment is not to eliminate the virus itself, but rather to manage the symptoms it causes and prevent potential complications. Most HPV infections clear up on their own within two years as the body’s immune system naturally fights off the virus, but some cases require medical attention.^[1]

Treatment decisions depend heavily on what problems the virus is causing. For instance, visible genital warts caused by low-risk HPV types need different management than precancerous changes in cervical cells caused by high-risk HPV types. The approach also varies based on where the infection is located, how many lesions are present, whether the person has a weakened immune system, and what treatments have been tried before. It’s important to note that available therapies can reduce symptoms and visible signs of infection, but they are unlikely to completely eliminate HPV infectivity from the body.^[13]

Current medical practice follows established guidelines that recommend regular screening for cervical cancer in women starting at age 21, allowing healthcare providers to detect precancerous cell changes before they progress to cancer. For genital warts, treatment focuses on removing visible lesions until the body’s immune system can better control viral replication. Beyond these standard approaches, ongoing clinical research is exploring new methods to better manage HPV-related health problems and prevent disease progression.^[1]

Standard Treatment Approaches for HPV-Related Conditions

There is no medication that can directly treat or cure the HPV virus itself. Instead, healthcare providers focus on treating the visible problems that HPV causes, such as genital warts and precancerous cell changes. The choice of treatment method depends on the specific condition being addressed.^[11]

Treatment of Genital Warts

For genital warts, several treatment options are available. Some involve medications that patients can apply at home, while others require procedures performed by healthcare professionals. Patient-applied treatments include imiquimod, a prescription cream that helps stimulate the immune system to fight HPV. Common side effects include swelling and redness where the cream is applied. Another option is podofilox, which works by destroying genital wart tissue, though it may cause burning and itching at the application site.^[10]

For warts on other parts of the body, over-the-counter products containing salicylic acid can be effective. These work by gradually removing layers of the wart tissue over time. However, salicylic acid products should never be used on genital warts, as they can cause unnecessary tissue damage in sensitive areas. Healthcare providers may also use trichloroacetic acid, a chemical treatment that burns off warts on various body areas including the genitals, though it can cause local irritation.^[10]

When medications don’t work effectively, healthcare providers can remove warts through various procedures. Cryotherapy, or freezing with liquid nitrogen, is a common method that destroys wart tissue through extreme cold. Another approach is surgical removal, where warts are physically cut away. Some providers use burning techniques to eliminate wart tissue. Improper use of these ablative treatments can lead to unnecessary tissue damage, so they must be performed carefully by trained professionals.^[13]

Treatment success varies considerably between individuals. Most patients require multiple treatment sessions over weeks to months before achieving complete clearance. If a treatment approach doesn’t show substantial improvement after three sessions, or if complete clearance isn’t achieved after six treatments, healthcare providers typically recommend switching to a different method. Recurrence of warts occurs in approximately 20 to 30 percent of patients regardless of which therapy is chosen, which can be frustrating but is a normal part of the treatment process.^[13]

Management of Precancerous Cell Changes

When HPV causes abnormal cell changes that could potentially progress to cancer, the treatment approach differs from wart management. For cervical changes detected through Pap smears or HPV screening tests, healthcare providers may recommend a waiting period with close monitoring, especially in younger women under 30, since many infections resolve naturally. Regular follow-up testing helps ensure any progression is caught early.^[1]

For more significant cervical changes, treatments may include medications applied directly to the affected area or various surgical procedures to remove abnormal cells. The specific approach chosen depends on the severity of cell changes, the location and extent of abnormal tissue, and individual patient factors such as age and pregnancy plans. These interventions aim to remove precancerous cells before they have the chance to develop into cervical cancer.^[8]

Special Considerations for Different Patient Groups

People with weakened immune systems, including those living with HIV or taking immunosuppressive medications, often experience more difficulty in clearing HPV infections. Their warts may not respond as well to standard therapies, and they frequently require multiple treatment methods or combinations of approaches. These patients also face higher rates of recurrence and may need more aggressive or prolonged treatment regimens.^[13]

Pregnant women who develop genital warts require special consideration. While warts may grow larger during pregnancy due to hormonal changes and immune system modifications, many treatment options are safe for use during pregnancy. However, some medications and procedures are avoided to protect the developing baby. In rare cases, HPV can be transmitted from mother to baby during childbirth, potentially causing respiratory papillomatosis, where warts develop in the infant’s throat.^[16]

Treatment in Clinical Trials

While standard treatments focus on managing symptoms and complications of HPV infection, researchers continue to explore new therapeutic approaches through clinical trials. These investigations aim to develop better methods for treating persistent HPV infections, preventing disease progression, and improving outcomes for patients with HPV-related conditions.

Clinical trials typically progress through three main phases. Phase I trials focus primarily on safety, testing new treatments in small groups to understand how the human body responds and what side effects might occur. Phase II trials expand the participant pool to evaluate whether the treatment actually works against the targeted condition. Phase III trials compare the new treatment against current standard approaches in large groups of participants to determine if it offers superior benefits.^[12]

Prevention Through Vaccination

The most significant advancement in HPV management has been the development of preventive vaccines. Three HPV vaccines have been licensed: a 2-valent vaccine targeting HPV types 16 and 18, a 4-valent vaccine targeting types 6, 11, 16, and 18, and a 9-valent vaccine (currently the only one available in the United States) that targets nine HPV types including 6, 11, 16, 18, 31, 33, 45, 52, and 58. These vaccines work by helping the body develop immunity before exposure to the virus.^[12]

The 9-valent vaccine offers the broadest protection, covering types responsible for approximately 66 percent of all cervical cancers (types 16 and 18) plus five additional types that account for another 15 percent. Types 6 and 11, also included in the vaccine, cause more than 90 percent of genital warts. Vaccination recommendations from the Advisory Committee on Immunization Practices include routine vaccination for all adolescents at age 11 or 12 years, with the possibility of starting as early as age 9. Catch-up vaccination is recommended through age 26 for those not previously vaccinated.^[12]

The vaccine schedule depends on age at initiation. Individuals who start vaccination before their 15th birthday need only two doses given at 0 and 6 to 12 months apart. Those beginning vaccination at age 15 or older require three doses at 0, 1 to 2, and 6 months. People with weakened immune systems need the three-dose schedule regardless of age. Prelicensure and postlicensure safety evaluations have confirmed that HPV vaccines are well tolerated, with more than 120 million doses distributed in the United States demonstrating robust safety data.^[12]

Impact monitoring studies in the United States have shown significant reductions in both genital warts and the specific HPV types contained in the vaccine since vaccination programs began. These real-world results demonstrate that the vaccines are not only safe but also highly effective at preventing HPV-related conditions when given before exposure to the virus.^[12]

Therapeutic Approaches Under Investigation

Beyond preventive vaccines, researchers are exploring therapeutic interventions that could help people who already have HPV infections. Since the virus works by producing specific proteins, particularly E6 and E7 proteins that interfere with normal cell growth control, some research focuses on blocking these proteins’ activities. These proteins are key players in how high-risk HPV types promote the development of precancerous changes and cancers.^[17]

Investigational approaches being studied include methods to enhance the body’s immune response against HPV-infected cells, since most HPV infections are eventually cleared by natural immune system activity. The challenge is that HPV has evolved ways to avoid immune detection, which is why some infections persist. Researchers are working to understand these immune evasion mechanisms and develop strategies to overcome them.

The goal of ongoing clinical research is to find treatments that can accelerate clearance of persistent HPV infections, more effectively treat precancerous lesions to prevent cancer development, and improve quality of life for people dealing with recurrent HPV-related conditions like genital warts. While many of these approaches are still in early stages of testing, they represent promising directions for future HPV management.

Most common treatment methods

• Topical medications for genital warts
  • Imiquimod cream applied by patients at home to stimulate immune response against warts, with common side effects of swelling and redness at application site
  • Podofilox solution applied to destroy wart tissue, though it may cause burning and itching sensations
  • Salicylic acid products for non-genital warts that work by gradually removing wart layers over time
  • Trichloroacetic acid applied by healthcare providers to chemically burn off warts
• Physical removal procedures
  • Cryotherapy using liquid nitrogen to freeze and destroy wart tissue
  • Surgical excision to physically cut away wart lesions
  • Burning techniques to eliminate wart tissue through controlled heat application
  • Multiple treatment sessions typically required over weeks to months for complete clearance
• Management of precancerous changes
  • Regular monitoring with Pap smears and HPV testing to detect cervical cell changes early
  • Watchful waiting for mild changes, especially in women under 30, since many infections resolve naturally
  • Removal procedures for more significant cell abnormalities to prevent progression to cancer
  • Follow-up testing schedules based on age, HPV test results, and severity of cell changes
• Preventive vaccination
  • 9-valent HPV vaccine protecting against nine HPV types that cause most cancers and genital warts
  • Routine vaccination recommended for adolescents at age 11 to 12 years
  • Two-dose schedule for those starting before age 15; three-dose schedule for those 15 and older
  • Catch-up vaccination available through age 26 for previously unvaccinated individuals